Published in Br J Pharmacol on January 14, 2008
Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol (2009) 1.42
Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci (2009) 1.42
Lipoxins: resolutionary road. Br J Pharmacol (2009) 1.35
Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. Am J Pathol (2009) 1.16
Resolvins: natural agonists for resolution of pulmonary inflammation. Prog Lipid Res (2010) 1.08
Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev (2011) 1.04
Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis (2011) 0.95
Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma. Prostaglandins Leukot Essent Fatty Acids (2012) 0.80
Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway. Br J Pharmacol (2014) 0.78
Molecular mechanism of the inhibition effect of Lipoxin A4 on corneal dissolving pathology process. Int J Ophthalmol (2013) 0.77
Walker 256 Tumor Growth Suppression by Crotoxin Involves Formyl Peptide Receptors and Lipoxin A4. Mediators Inflamm (2016) 0.75
Aspirin modulates innate inflammatory response and inhibits the entry of Trypanosoma cruzi in mouse peritoneal macrophages. Mediators Inflamm (2014) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16
Angiogenesis in health and disease. Nat Med (2003) 14.02
Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer (2003) 6.65
Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol (2007) 5.83
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature (1996) 5.40
Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest (2001) 4.92
Aspirin as prophylaxis against colorectal cancer. N Engl J Med (1995) 3.83
Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A (1995) 3.72
Protein-tyrosine phosphatases and cancer. Nat Rev Cancer (2006) 3.65
VEGF-receptor signal transduction. Trends Biochem Sci (2003) 2.89
The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev (2006) 2.80
Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med (1994) 2.38
Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol Cell Biol (1998) 2.35
VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans (2003) 2.31
The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem (1997) 2.07
Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett (1998) 2.05
Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res (2003) 1.98
Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer (2003) 1.98
Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med (1996) 1.92
Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Thromb Haemost (2007) 1.74
Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol (2005) 1.74
PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem (2002) 1.63
A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal (2005) 1.58
Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem (1995) 1.55
Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A (2002) 1.54
The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem (1999) 1.44
Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J (2003) 1.41
Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol (2000) 1.38
Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. J Biol Chem (2002) 1.32
Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. Proc Natl Acad Sci U S A (1999) 1.29
Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest (1996) 1.27
Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther (2002) 1.27
Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci (1993) 1.23
Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology (2003) 1.17
Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem (2000) 1.15
Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. Biochem Biophys Res Commun (2005) 1.12
Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor. Am J Respir Cell Mol Biol (2005) 1.12
Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene (2006) 1.06
Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci (2004) 1.03
Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J Biol Chem (2000) 1.01
Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets (2006) 0.99
Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J (2002) 0.98
Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am J Pathol (2004) 0.97
Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int J Immunopathol Pharmacol (2004) 0.94
Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma. Am J Respir Crit Care Med (2006) 0.94
Aspirin and other anti-inflammatory drugs. Thorax (2000) 0.93
Quantitative analysis of matrix metalloproteinases-2 and -9, and their tissue inhibitors-1 and -2 in human placenta throughout gestation. Life Sci (2000) 0.89
Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int (2005) 0.89
Downregulation of platelet-derived growth factor receptor-beta in Shp-2 mutant fibroblast cell lines. Oncogene (1998) 0.88
Involvement of the Rho-kinase/myosin light chain kinase pathway on human monocyte chemotaxis induced by ATL-1, an aspirin-triggered lipoxin A4 synthetic analog. J Immunol (2005) 0.85
The Lipoxin A4 receptor is coupled to SHP-2 activation: implications for regulation of receptor tyrosine kinases. J Biol Chem (2007) 0.85
Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. J Thromb Haemost (2003) 0.83
Involvement of matrix metalloproteinase-9 in platelet-activating factor-induced angiogenesis. FEBS Lett (2005) 0.82
Effects of aspirin and indomethacin on endothelial cell proliferation in vitro. J Gastroenterol Hepatol (2003) 0.80
Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. Int J Cardiol (2004) 0.76
Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med (2000) 2.01
Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol (2005) 1.74
Heme oxygenase/carbon monoxide-biliverdin pathway down regulates neutrophil rolling, adhesion and migration in acute inflammation. Br J Pharmacol (2006) 1.10
Cutting edge: nociceptin stimulates neutrophil chemotaxis and recruitment: inhibition by aspirin-triggered-15-epi-lipoxin A4. J Immunol (2001) 1.09
Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene (2006) 1.06
A role for the MAPK/ERK pathway in oligodendroglial differentiation in vitro: stage specific effects on cell branching. Int J Dev Neurosci (2009) 1.01
The involvement of nitric oxide in the anti-Candida albicans activity of rat neutrophils. Immunology (1996) 0.99
Induction of NOS in rat blood PMN in vivo and in vitro: modulation by tyrosine kinase and involvement in bactericidal activity. J Leukoc Biol (1999) 0.97
Production of reactive oxygen species by hemocytes from the cattle tick Boophilus microplus. Exp Parasitol (2001) 0.93
Virulence of Sporothrix schenckii conidia and yeast cells, and their susceptibility to nitric oxide. Immunology (2000) 0.93
Jararhagin, a snake venom metalloproteinase, induces a specialized form of apoptosis (anoikis) selective to endothelial cells. Apoptosis (2005) 0.93
The contribution of extensin network formation to rapid, hydrogen peroxide-mediated increases in grapevine callus wall resistance to fungal lytic enzymes. J Exp Bot (2006) 0.88
Neutrophil function in severe sepsis. Endocr Metab Immune Disord Drug Targets (2006) 0.88
Rat paw edema and leukocyte immigration induced by plant lectins. Agents Actions (1993) 0.88
Influence of beverage composition on the results of erosive potential measurement by different measurement techniques. Caries Res (2008) 0.87
Estimated erosive potential depends on exposure time. J Dent (2012) 0.86
Reduction of erosive wear in situ by stannous fluoride-containing toothpaste. Caries Res (2011) 0.86
Heme modulates smooth muscle cell proliferation and migration via NADPH oxidase: a counter-regulatory role for heme oxygenase system. Atherosclerosis (2012) 0.85
Effect of salivary factors on the susceptibility of hydroxyapatite to early erosion. Caries Res (2011) 0.84
Canatoxin, a toxic protein from jack beans (Canavalia ensiformis), is a variant form of urease (EC 3.5.1.5): biological effects of urease independent of its ureolytic activity. Biochem J (2001) 0.83
Gunshot wound and bullet 'aspiration'. Pediatr Radiol (2001) 0.81
Hypoxemia modifies circulating and exudate neutrophil number and functional responses in carrageenin-induced pleurisy in the rat. J Leukoc Biol (2000) 0.81
Studies on the anti-allergic activity of Mikania glomerata. J Ethnopharmacol (1999) 0.80
Inflammatory and anti-inflammatory effects of soybean agglutinin. Braz J Med Biol Res (1997) 0.78
Lymphocyte activation and cytokine production by Pisum sativum agglutinin (PSA) in vivo and in vitro. Immunopharmacology (1999) 0.78
Pharmacological characterization of rat paw edema induced by canatoxin, the toxic protein from Canavalia ensiformis (jack bean) seeds. Toxicon (1992) 0.78
Anti-inflammatory profile of N-phenylpyrazole arylhydrazone derivatives in rats. J Pharm Pharmacol (1999) 0.78
Procoagulant properties of human MV3 melanoma cells. Braz J Med Biol Res (2008) 0.77
A synthetic analog of 15-epi-lipoxin A4 inhibits human monocyte apoptosis: involvement of ERK-2 and PI3-kinase. Prostaglandins Other Lipid Mediat (2009) 0.76
Effects of jarastatin, a novel snake venom disintegrin, on neutrophil migration and actin cytoskeleton dynamics. Exp Cell Res (1999) 0.76
Canatoxin induces activation on mice peritoneal macrophages. Braz J Med Biol Res (1992) 0.76
An increase in nitric oxide produced by rat peritoneal neutrophils is not involved in cell apoptosis. Mediators Inflamm (1995) 0.75
Reduction of erosion by protein-containing toothpastes. Caries Res (2012) 0.75
Astroglial differentiation in the opossum superior colliculus. Glia (1989) 0.75
The regional distribution of neuronal glycogen in the opossum brain, with special reference to hypothalamic systems. J Neurocytol (1996) 0.75
Fluid-structure effects of cloaking a submerged spherical shell. J Acoust Soc Am (2013) 0.75